Non Squamous Non Small Cell Lung Cancer
Conditions
Keywords
Recurrent Lung Cancer, Stage IV Lung Cancer, OGX-427, Sarah Cannon Research Institute, SCRI, OncoGenex, NSCLC, Non Small Cell Lung Cancer
Brief summary
This randomized phase II study will compare the efficacy and safety of the combination of carboplatin and pemetrexed with and without OGX-427 in patients with previously untreated advanced non-squamous NSCLC.
Detailed description
Modern doublet chemotherapy improves survival in patients with advanced non-small cell lung cancer (NSCLC) compared with supportive care alone, with non-squamous NSCLC patients treated with platinum/pemetrexed living longer than patients treated with platinum/gemcitabine. Despite these advances, poor outcomes with advanced disease warrant exploration of novel drugs with unique mechanisms of action. Preclinical evidence in lung cancer models shows promising antitumor activity with OGX-427 in combination with platinum based therapy or pemetrexed. In this double-blind, placebo-controlled, Phase II study, pemetrexed and carboplatin plus OGX-427 followed by maintenance pemetrexed and OGX-427 will be compared with pemetrexed and carboplatin plus placebo followed by maintenance pemetrexed and placebo in patients with previously untreated advanced non-squamous NSCLC.
Interventions
DRUGOGX-427
Three loading doses of 600mg OGX-427 will be administered intravenously (IV) during a 9 day period. Then 600mg IV OGX-427 will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive 600 mg IV OGX-427 plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
DRUGPlacebo
Three loading doses of placebo will be administered intravenously (IV) during a 9 day period. Then placebo (IV) will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive placebo (IV) plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
Sponsors
Achieve Life Sciences
SCRI Development Innovations, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologic or cytologic diagnosis of advanced NSCLC, excluding squamous cell and small cell histology. Tumors with mixed NSCLC histologies are eligible, as long as the predominant histology is not squamous. If small-cell elements are present or not otherwise specified histologically, the patient is not eligible. 2. Metastatic disease (according to American Joint Committee on Cancer (AJCC) staging system, v7.0). 3. No prior systemic chemotherapy, immunotherapy, targeted therapy, or biological therapy for metastatic disease; previous adjuvant or neoadjuvant therapy for Stage I, II, or III disease is allowed as long as the interval from the end of treatment until disease progression was \>12 months. 4. No prior radiation therapy to the whole pelvis or to ≥25% of the total bone marrow area. Other radiation therapy must be completed at least 2 weeks prior to study entry. Must have recovered from acute adverse effects prior to study entry. 5. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 6. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. 7. Baseline laboratory values as follows: * Absolute neutrophil count (ANC) ≥1500/μL * Hemoglobin (Hgb) ≥10 g/dL * Platelets ≥100,000/μL * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), ≤3.0 x the upper limit of normal (ULN); 5 x ULN if known hepatic metastases. * Total bilirubin ≤1.5 x ULN, unless secondary to Gilbert's disease * Serum creatinine ≤1.5 x ULN. If creatinine is \>1.5, calculate creatinine clearance (CrCl) ≥45 mL/min by the Cockcroft-Gault method: Glomerular Filtration Rate (GFR) = (140-age) x (weight/kg) x (0.85 if female)/(72 x serum creatinine mg/dL) 8. Fertile male patients willing to use adequate contraceptive measures. 9. Female patients who are not of child-bearing potential, and fertile female patients of child-bearing potential who agree to use adequate contraceptive measures, who are not breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours prior to start of randomization. 10. Life expectancy ≥ 12 weeks. 11. Must be ≥18 years of age at the time of consent. 12. Willingness and ability to comply with trial and follow-up procedures. 13. Ability to understand the nature of this trial and give written informed consent.
Exclusion criteria
1. Known anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) activating mutations where first-line treatment with targeted tyrosine kinase inhibitor therapy is more appropriate. 2. Known central nervous system (CNS) disease other than neurologically stable, treated brain metastases defined as metastasis having no evidence of progression or hemorrhage after treatment and no ongoing requirements for corticosteroids, (e.g., dexamethasone) for at least 2 weeks. 3. Any of the following cardiac diseases currently or within the last 6 months as defined by New York Heart Association (NYHA) ≥ Class 2: * Unstable angina pectoris * Congestive heart failure * Acute myocardial infarction * Conduction abnormality not controlled with pacemaker or medication * Significant ventricular or supraventricular arrhythmias (Patients with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible). 4. Patients currently receiving therapeutic anticoagulation. 5. Pregnant or lactating women. 6. Any serious, active underlying medical condition that would impair the ability of the patient to receive study treatment, such as diabetes mellitus or infection. 7. Unable or unwilling to take folic acid or vitamin B12. 8. Active second malignancy (except non-melanomatous skin or superficial bladder cancer) defined as requiring current need for cancer therapy or at high risk of recurrence (\>30%) during the study. 9. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol. 10. Inability or unwillingness to comply with trial and/or follow-up procedures outlined in the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Median Progression-Free Survival | Every 6 weeks for up to 24 months | Defined as the time (in months) from date of randomization to the date of first observation of progression based on radiological assessment by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1, or date of death from any cause, in the absence of progressive disease (PD) or censored at the date of last adequate tumor assessment. Progressive Disease is defined by RECIST v1.1 as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest (nadir) sum while on study (this includes the baseline sum if that is the smallest on study), or the appearance of one or more new lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of OGX-427 Versus Placebo Participants With an Objective Response | Every 6 weeks for up to 24 months | Defined as the number of patients with objective evidence of complete or partial response (CR or PR) using RECIST v 1.1. A CR is the complete disappearance of all target lesions. A PR is a decrease in baseline of 30% or more of the diameter(s) of all target lesions. |
| Median Overall Survival | Every 6 weeks for up to 41 months | Defined as the time (in months) from date of randomization to date of death from any cause, or censored at the date last known alive. |
| Number of Patients With a Treatment-Related Adverse Event as a Measure of Safety. | Weekly during each 21 days cycle and for 30 days after last dose for up to 29 Months | A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. |
Countries
United States
Participant flow
Recruitment details
Between August 2013 and February 2015, a total of 155 patients (77 patients on the OGX-427 (apatorsen) arm and 78 patients on the placebo arm) were enrolled and randomized on the study.
Pre-assignment details
Subjects were enrolled and randomized in a 1:1 ratio to receive a combination of pemetrexed and carboplatin plus either OGX-427 (apatorsen) or a placebo.
Participants by arm
| Arm | Count |
|---|---|
| OGX-427 OGX-427: Three loading doses of OGX-427 at 600mg intravenously (IV) will be administered over 9 days.
Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle. OGX-427 will be given prior to the administration of pemetrexed (500mg/m2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle. A maximum of four treatment cycles will be administered.
Patients without toxicity or disease progression after four cycles of therapy will move on to a Maintenance Phase of OGX-427 administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle plus pemetrexed (500mg/m2 IV on Day 1). Patients may remain on maintenance as long as they are benefiting and have no evidence of disease progression. | 77 |
| Placebo Placebo: Three loading doses of placebo will be administered intravenously (IV) over 9 days.
Following the loading dose period, placebo will be administered IV weekly Days 1, 8 and 15 of each 21 day cycle. Placebo will be given prior to the administration of pemetrexed (500mg/m2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle. A maximum of four treatment cycles will be administered.
Patients without toxicity or disease progression after four cycles of therapy will move on to a Maintenance Phase of placebo administered IV weekly Days 1, 8 and 15 of each 21 day cycle plus pemetrexed (500mg/m2 IV on Day 1). Patients may remain on maintenance as long as they are benefiting and have no evidence of disease progression. | 78 |
| Total | 155 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 14 | 10 |
| Overall Study | Death | 4 | 6 |
| Overall Study | Disease Progression | 37 | 48 |
| Overall Study | No Study Treatment Received | 3 | 2 |
| Overall Study | Physician Decision | 1 | 1 |
| Overall Study | Sponsor Decision | 1 | 1 |
| Overall Study | Withdrawal by Subject | 17 | 10 |
Baseline characteristics
| Characteristic | Placebo | Total | OGX-427 |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 49 Participants | 91 Participants | 42 Participants |
| Age, Categorical Between 18 and 65 years | 29 Participants | 64 Participants | 35 Participants |
| Age, Continuous | 67 years | 66 years | 66 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 13 Participants | 10 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 74 Participants | 141 Participants | 67 Participants |
| Region of Enrollment United States | 78 Participants | 155 Participants | 77 Participants |
| Sex: Female, Male Female | 40 Participants | 79 Participants | 39 Participants |
| Sex: Female, Male Male | 38 Participants | 76 Participants | 38 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 56 / 77 | 61 / 78 |
| other Total, other adverse events | 72 / 74 | 75 / 76 |
| serious Total, serious adverse events | 35 / 74 | 32 / 76 |
Outcome results
Primary
Median Progression-Free Survival
Defined as the time (in months) from date of randomization to the date of first observation of progression based on radiological assessment by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1, or date of death from any cause, in the absence of progressive disease (PD) or censored at the date of last adequate tumor assessment. Progressive Disease is defined by RECIST v1.1 as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest (nadir) sum while on study (this includes the baseline sum if that is the smallest on study), or the appearance of one or more new lesions.
Time frame: Every 6 weeks for up to 24 months
Population: All patients who were randomized
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| OGX-427 | Median Progression-Free Survival | 6 months |
| Placebo | Median Progression-Free Survival | 4.9 months |
Secondary
Median Overall Survival
Defined as the time (in months) from date of randomization to date of death from any cause, or censored at the date last known alive.
Time frame: Every 6 weeks for up to 41 months
Population: All patients who were randomized.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| OGX-427 | Median Overall Survival | 10.8 Months |
| Placebo | Median Overall Survival | 11.8 Months |
Secondary
Number of OGX-427 Versus Placebo Participants With an Objective Response
Defined as the number of patients with objective evidence of complete or partial response (CR or PR) using RECIST v 1.1. A CR is the complete disappearance of all target lesions. A PR is a decrease in baseline of 30% or more of the diameter(s) of all target lesions.
Time frame: Every 6 weeks for up to 24 months
Population: All patients who were randomized.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| OGX-427 | Number of OGX-427 Versus Placebo Participants With an Objective Response | 21 Participants |
| Placebo | Number of OGX-427 Versus Placebo Participants With an Objective Response | 25 Participants |
Secondary
Number of Patients With a Treatment-Related Adverse Event as a Measure of Safety.
A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
Time frame: Weekly during each 21 days cycle and for 30 days after last dose for up to 29 Months
Population: Randomized patients who received at least one dose of study treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| OGX-427 | Number of Patients With a Treatment-Related Adverse Event as a Measure of Safety. | 63 Participants |
| Placebo | Number of Patients With a Treatment-Related Adverse Event as a Measure of Safety. | 70 Participants |